{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:39:31Z","timestamp":1791859171951,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/CDRF\/21\/21032"],"award-info":[{"award-number":["FS\/CDRF\/21\/21032"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"NIHR Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203326"],"award-info":[{"award-number":["NIHR203326"]}],"id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020643","name":"MRC","doi-asserted-by":"publisher","award":["HDRUK\/CFC\/01"],"award-info":[{"award-number":["HDRUK\/CFC\/01"]}],"id":[{"id":"10.13039\/501100020643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Anaemia is common in patients with chronic heart failure (CHF), worsening functional status and prognosis. The role of erythropoiesis-stimulating agents (ESAs) to reduce hospitalization remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A pre-registered systematic search was performed of randomized controlled trials in adults with CHF and anaemia, comparing any ESA at any dose versus placebo or no treatment.<\/jats:p>\n                    <jats:p>Fourteen trials were included with 3128 participants, with moderate quality of evidence for most outcomes and variable risk of bias. Meta-analysis during 5604 person-years of follow-up demonstrated no significant difference in first CHF hospitalization comparing ESAs with control: Peto odds ratio (OR) 0.93, 95% CI 0.78\u20131.10, P = .37; trial heterogeneity I2 = 36%. ESAs significantly reduced total CHF hospitalization with 622 events\/2698 person-years, compared with 761\/2914 person-years for control: incidence rate ratio 0.81, 95% CI 0.73 to 0.90, P &amp;lt; .001; no heterogeneity between trials, I2 = 0%. There were no significant differences between treatment groups for all-cause mortality (OR 1.01, 95% CI 0.86\u20131.18, P = .88; I2 = 35%) or incident adverse events. Patients randomized to ESAs increased their haemoglobin level [mean difference (MD) 1.6\u2005g\/dL compared with control, 95% CI 1.6\u20131.7, P &amp;lt; .001] and exercise tolerance (MD 69 metres, 95% CI 17\u2013122, P = .009), with lower NYHA class on follow-up (MD \u22120.73 class, 95% CI \u22121.11 to \u22120.36, P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ESA treatment in patients with CHF and mild anaemia can reduce recurrent CHF hospitalization and improve functional capacity, without any impact on adverse events. Including ESAs in CHF management could be considered in patients with anaemia at high risk of recurrent hospital admissions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuaf012","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:31:28Z","timestamp":1767702688000},"page":"85-95","source":"Crossref","is-referenced-by-count":2,"title":["Erythropoiesis-stimulating agents to reduce heart failure hospitalization: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-4377","authenticated-orcid":false,"given":"Karina V","family":"Bunting","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham ,","place":["UK"]},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust , Mindelsohn Way, Birmingham B15 2TH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-122X","authenticated-orcid":false,"given":"Otilia","family":"Tica","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham ,","place":["UK"]},{"name":"Cardiology Clinic, Emergency County Clinical Hospital of Bihor , Oradea ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgher","family":"Champsi","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham ,","place":["UK"]},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust , Mindelsohn Way, Birmingham B15 2TH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Perrett","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G","family":"von Lueder","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-7935","authenticated-orcid":false,"given":"Dirk J","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Centre Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D","family":"Flather","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia and Norfolk and Norwich University Hospital , Norwich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-9812","authenticated-orcid":false,"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham ,","place":["UK"]},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust , Mindelsohn Way, Birmingham B15 2TH ,","place":["UK"]},{"name":"Julius Center, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026050209115007600_xuaf012-B1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"key":"2026050209115007600_xuaf012-B2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"2026050209115007600_xuaf012-B3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ahj.2011.02.013","article-title":"Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials","volume":"161","author":"Kotecha","year":"2011","journal-title":"Am Heart J"},{"key":"2026050209115007600_xuaf012-B4","doi-asserted-by":"publisher","first-page":"ii13","DOI":"10.1093\/europace\/eur081","article-title":"What are the costs of heart failure?","volume":"13","author":"Braunschweig","year":"2011","journal-title":"Europace"},{"key":"2026050209115007600_xuaf012-B5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD","volume":"62","author":"Kliger","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026050209115007600_xuaf012-B6","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated Anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026050209115007600_xuaf012-B7","doi-asserted-by":"publisher","first-page":"CD007613","DOI":"10.1002\/14651858.CD007613","article-title":"Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients","volume":"1","author":"Ngo","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026050209115007600_xuaf012-B8","doi-asserted-by":"publisher","first-page":"e011130","DOI":"10.1161\/JAHA.118.011130","article-title":"Epoetin Beta and C-terminal fibroblast growth factor 23 in patients with chronic heart failure and chronic kidney disease","volume":"8","author":"Eisenga","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026050209115007600_xuaf012-B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1557-4679.1168","article-title":"Mixed-effects poisson regression models for meta-analysis of follow-up studies with constant or varying durations,","volume":"5","author":"Bagos","journal-title":"Int J Biostat"},{"key":"2026050209115007600_xuaf012-B10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/01.fjc.0000167013.77092.c4","article-title":"Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation","volume":"46","author":"Cleland","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026050209115007600_xuaf012-B11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","article-title":"Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia","volume":"117","author":"Ghali","year":"2008","journal-title":"Circulation"},{"key":"2026050209115007600_xuaf012-B12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/HJR.0b013e3282f849d0","article-title":"Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure","volume":"15","author":"Kourea","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026050209115007600_xuaf012-B13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","article-title":"Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure","volume":"107","author":"Mancini","year":"2003","journal-title":"Circulation"},{"key":"2026050209115007600_xuaf012-B14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1161\/CIRCHEARTFAILURE.112.969717","article-title":"Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy","volume":"6","author":"Maurer","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026050209115007600_xuaf012-B15","doi-asserted-by":"publisher","first-page":"1096.e9","DOI":"10.1016\/j.ahj.2006.08.005","article-title":"Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia","volume":"152","author":"Palazzuoli","year":"2006","journal-title":"Am Heart J"},{"key":"2026050209115007600_xuaf012-B16","doi-asserted-by":"publisher","first-page":"645.e9","DOI":"10.1016\/j.ahj.2007.07.022","article-title":"Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome","volume":"154","author":"Palazzuoli","year":"2007","journal-title":"Am Heart J"},{"key":"2026050209115007600_xuaf012-B17","doi-asserted-by":"publisher","first-page":"751.e1","DOI":"10.1016\/j.ahj.2008.01.016","article-title":"Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"155","author":"Parissis","year":"2008","journal-title":"Am Heart J"},{"key":"2026050209115007600_xuaf012-B18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2006.11.024","article-title":"Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial","volume":"49","author":"Ponikowski","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026050209115007600_xuaf012-B19","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia","volume":"28","author":"van Veldhuisen","year":"2007","journal-title":"Eur Heart J"},{"key":"2026050209115007600_xuaf012-B20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"2026050209115007600_xuaf012-B21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijcard.2008.06.064","article-title":"Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients","volume":"138","author":"Cosyns","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026050209115007600_xuaf012-B22","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","article-title":"The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study","volume":"37","author":"Silverberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026050209115007600_xuaf012-B23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/hrt.2008.161091","article-title":"Erythropoietin treatment in patients with chronic heart failure: a meta-analysis","volume":"95","author":"van der Meer","year":"2009","journal-title":"Heart"},{"key":"2026050209115007600_xuaf012-B24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.112.125435","article-title":"Rehospitalization for heart failure: predict or prevent?","volume":"126","author":"Desai","year":"2012","journal-title":"Circulation"},{"key":"2026050209115007600_xuaf012-B25","doi-asserted-by":"publisher","author":"Champsi","DOI":"10.2139\/ssrn.4544769"},{"key":"2026050209115007600_xuaf012-B26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"2026050209115007600_xuaf012-B27","doi-asserted-by":"publisher","first-page":"100933","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis","volume":"36","author":"Cardoso","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026050209115007600_xuaf012-B28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026050209115007600_xuaf012-B29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026050209115007600_xuaf012-B30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuaf012\/66500583\/xuaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/1\/85\/66500583\/xuaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/1\/85\/66500583\/xuaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:11:57Z","timestamp":1777727517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/1\/85\/8433874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuaf012","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}